Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Sarcoma 4Lymphoma, Non-Hodgkin 4Lymphoma, Follicular 4Rhabdoid Tumor 3Lymphoma, B-Cell 3Wilms Tumor 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Prostatic Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, T-Cell 2Lymphoma 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Xanthogranuloma, Juvenile 1Urinary Bladder Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Recurrence 1Ovarian Neoplasms 1Neurofibrosarcoma 1Nerve Sheath Neoplasms 1Melanoma 1Lymphoma, T-Cell, Peripheral 1

Interventions

Cyclophosphamide 5Etoposide 3duvelisib 2Vincristine 2Prednisone 2Melphalan 2Doxorubicin 2Azacitidine 210-propargyl-10-deazaaminopterin 2tazemetostat 1sodium-iodide symporter 1ruxolitinib 1pembrolizumab 1fludarabine phosphate 1fludarabine 1etoposide phosphate 1cemiplimab 1belinostat 1X-Rays 1Whole-Body Irradiation 1Tacrolimus 1Specimen Handling 1Sirolimus 1Prednisolone 1Photons 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Mycophenolic Acid 1Methotrexate 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immunoblastic Lymphadenopathy × tazemetostat × 90 days × Clear all
NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡